TWST Company Profile and Key Details

TWST has shown sold momentum, gaining 9.49% over the past week and 47.9% over the past quarter, though year-to-date performance is up 31.31%. Short-term trend indicators are bearishly aligned (SMA20 0.75%, SMA50 17.68%, SMA200 45.11%). The stock’s 14-day RSI is 55.34 (neutral), while the ATR of 3.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.84% below its high and over 109.06% above its low. Average 10-day trading volume of 1.31 million shares is in line with the 3-month average of 1.33 million, indicating normal recent market interest.

Twist Bioscience Corporation generated EPS of -$1.27 over the past year. Five-year average earnings growth is 18.31%. Wall Street analysts project EPS growth of 23.15% annually over the next five years. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at -$0.48. Next year's EPS is expected at $15.44. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $55.00 to $37.00. The high target offers 9.54% upside. The low target suggests -26.31% downside. The mean target is $45.17. This offers -10.04% upside. Twist Bioscience Corporation earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -10.17%. The prior quarter beat by -12.96%. Over the last six quarters, Apple has recorded several small beats. These include 86.29% in August 02, 2024.

Twist Bioscience Corporation (NASDAQ:TWST) closed at $50.21 USD, gaining $0.67 (1.35%) from the previous close of $49.54. The stock is currently mid-range between its 52-week high and low $23.30 and $57.88. With a market capitalization of about $3.08 billion, Twist Bioscience Corporation is classified as a mid-cap and shows higher-than-market volatility (beta ~2.29). Key stats such as the average daily volume over the past year has been around 1.33 million shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Twist Bioscience Corporation operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Emily Marine Leproust, the company employs approximately 923 people and listed since October 31, 2018. Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.

Twist Bioscience Corporation has 60.36 million shares outstanding. The public float is 59.24 million shares, elevated short interest at 19.13% of float. This equals 10.23 million shares. The short ratio is 5.61 days. Institutional investors hold 122.94% of the float. Insiders own 2.58%. Leproust Emily M. holds 858.89 thousand shares, Banyai William has 345.19 thousand shares and Finn Patrick John has 284.13 thousand shares. Over the past six months, insider transactions show net selling. They sold 331.13 thousand shares across 67 transactions.

Twist Bioscience Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $11.19. This means the shares are trading above this model’s fair value.

Twist Bioscience Corporation trades at a P/E ratio of -40.14, slightly below the S&P 500 average, with a price-to-sales ratio of 7.88 and a price-to-book ratio of 6.74 trading at moderately above to book value. The P/FCF stands at -35.58, also below market averages.

Twist Bioscience Corporation (NASDAQ:TWST) shares are up 31.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Twist Bioscience Corporation trading at a premium to the broader market with a P/E of -40.14. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $48.72, suggesting -2.97% downside. Our AI forecast model points to short-term weakness (-5.56% over two weeks), a medium-term rise (6.95% over three months), and a longer-term gain (19.82% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Twist Bioscience Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.56%, with price expected at $47.42 by April 16, 2026, within a range of $45.12 to $49.71 3-Month Outlook: Projected rise of 6.95%, reaching $53.70 by July 01, 2026, with a range of $51.44 to $56.13. 1-Year Outlook: Projected gain of 19.82%, with price at $60.16 by April 02, 2027, within a range of $56.53 to $63.73.